Driving Development of Allogeneic Cell Therapies and CAR-T with Novel Signalling Technologies
Time: 6:00 pm
day: Day 1 – Track B – Evening
Details:
- Leveraging naturally occurring multifunctional T-cell populations that harness innate and adaptive cell function
- Developing non-gene edited allogeneic CAR-T therapies on a novel gamma-delta platform
- Evolving platform capabilities using novel technologies for enhancement
